Share price movements
On March 12, MannKind Corporation (MNKD) closed at $2.09, 8.29% higher than its previous closing price, 122.34% higher than its 52-week low of $0.94, and 31.25% lower than its 52-week high of $3.04. The company’s market cap was $395.85 million, and its PS (price-to-sales) and PC (price-to-cash) multiples were 24.14x and 5.56x, respectively.
Since its fourth-quarter earnings release on February 26, MannKind stock has risen 38.41% from $1.51 on February 25 to $2.09 on March 12. On February 26, the stock closed at $1.76, 16.56% higher than its previous closing price. The company, however, missed both the consensus revenue estimate and the consensus EPS estimate by $7.47 million and $0.28, respectively, in the fourth quarter.
On March 12, Akebia Therapeutics (AKBA) closed at $8.10, 10.35% higher than its previous closing price, 55.77% higher than its 52-week low of $5.20, and 43.48% lower than its 52-week high of $14.33. The company’s market cap is $968.27 million, and its PS and PC ratios are 4.12x and 2.48x, respectively.
According to a press release, Akebia Therapeutics will be announcing its fiscal 2018 fourth-quarter and fiscal 2018 results on March 18, 2019.
Akebia Therapeutics is trading at lower PB and PC ratios than Mannkind Corporation. Both MannKind and Akebia are small-cap stocks and can prove more volatile and risky for retail investors than large-cap stocks or the broader market.
Analysts’ recommendations and target prices
The 12-month consensus recommendations for MannKind and Akebia Therapeutics are “strong buys” and “buys,” respectively.
Of the two analysts covering MannKind, one has given it a “strong buy” recommendation, while the other has given it a “buy” recommendation. The stock’s 12-month target price is $3.5, 67.46% higher than its closing price on March 12. The highest target price estimate for the company is $4, and the lowest is $3.
Of the seven analysts covering Akebia Therapeutics, one analyst has given it a “strong buy” rating, four have given it “buys,” and the remaining two have given it “holds.” Analysts’ 12-month target price is $18.88, 133.09% higher than its closing price on March 12. The highest target price estimate for the company is $30, and the lowest is $9.
Next, we’ll look at the revenue growth trajectories of MannKind Corporation and Akebia Therapeutics in greater detail.